3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
32
Pain, Postoperative
18
Neoplasms
15
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Lung Neoplasms
12
Brain Neoplasms
12
Prostatic Neoplasms
9
Ovarian Neoplasms
8
Colonic Neoplasms
8
Carcinoma, Hepatocellular
8
Stomach Neoplasms
7
Depression
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Pain
6
Head and Neck Neoplasms
6
Thyroid Neoplasms
5
Pancreatic Neoplasms
5
Multiple Myeloma
5
Leiomyoma
5
Agnosia
5
Neoplasm Metastasis
4
Lymphoma
4
Fatigue
4
Delirium
4
Anxiety Disorders
4
Urinary Bladder Neoplasms
3
Thromboembolism
3
Supratentorial Neoplasms
3
Stomatitis
3
Interventions
Etoposide
154
Carboplatin
142
Cisplatin
104
Topotecan
74
durvalumab
48
atezolizumab
46
Irinotecan
44
pembrolizumab
39
Paclitaxel
34
Nivolumab
33
Radiotherapy
29
anlotinib
23
PM 01183
22
Gemcitabine
21
Drug Therapy
20
apatinib
19
Ipilimumab
18
Docetaxel
17
Temozolomide
16
Platinum
16
Radiosurgery
15
Pemetrexed
14
toripalimab
13
tislelizumab
13
olaparib
13
Bevacizumab
13
amrubicin
11
Magnetic Resonance Spectroscopy
11
Cyclophosphamide
11
rovalpituzumab tesirine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Small Cell Lung Carcinoma
×
Saline Solution
×
Clear all
NCT03066778
2022-10-03
KEYNOTE-604
Merck Sharp & Dohme LLC
Phase 3
Completed
453 enrolled
23 charts